Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 13th January 2021
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer announces collaboration with PetMedix
PetMedix's Ky9 platform can rapidly and efficiently generate fully canine therapeutic antibodies.
Partnership will see the development of companion animal antibody therapeutics.

Boehringer Ingelheim has announced a multi-year partnership with PetMedix - a Cambridge-based biopharmaceutical firm - to develop novel and transformative companion animal antibody therapeutics.

The collaboration will see PetMedix undertake discovery activities against a number of key targets and Boehringer Ingelheim will work to develop and bring these therapies to market. The terms of the partnership have not been disclosed. 

PetMedix’s breakthrough approach to therapeutic antibodies has resulted in a number of successful, novel therapies for humans. It is also the only company in the world that has been able to bring this approach to veterinary medicine.

Through its its Ky9™ platform, PetMedix can rapidly and efficiently generate fully canine therapeutic antibodies. This approach saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies.

Dr Tom Weaver, CEO of PetMedix, said: “We are excited to be working with Boehringer Ingelheim on this project as we feel we bring complementary experience and expertise to this partnership. PetMedix has developed the leading pet antibody discovery engine, and it will be through Boehringer Ingelheim’s global scale and industry leadership that these novel therapies will best be able to succeed and ultimately benefit the animals.”

James Allan, global head of transaction, business development & licensing, Boehringer Ingelheim Animal Health, added: “Boehringer Ingelheim is pleased to be working with PetMedix on this cutting edge technology as a means to bring innovative new therapies to improve the health of animals globally. PetMedix has a unique expertise and its focus on innovation aligns well with our own”.

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
RCVS pays tribute to well-loved equine vet

The RCVS and the Riding Establishments Subcommittee has paid tribute to well-loved veterinary surgeon and riding establishment inspector, Rebecca Hamilton-Fletcher MRCVS.

Linda Belton MRCVS, RCVS President, said: "I, along with my colleagues on the RESC, RCVS Council, RCVS Standards Committee, as well as RCVS staff, was very saddened to hear of the sudden death of Rebecca, or Becca as we knew her, last week.

"She was a true advocate for equine welfare and in her many years on the RESC worked to continually improve the quality and consistency of riding establishment inspections, all in the interests of enhanced horse welfare and rider safety."